Please login to the form below

Not currently logged in
Email:
Password:

divestments

This page shows the latest divestments news and features for those working in and with pharma, biotech and healthcare.

Analysts lukewarm on GSK’s new cancer acquisition

Analysts lukewarm on GSK’s new cancer acquisition

That assessment comes even though GSK has offset the purchase with the divestment of Horlicks and other consumer healthcare nutrition products to Unilever, which will bring in around £2.4bn (around

Latest news

More from news
Approximately 2 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal Watch over the last few months but focused more on the company's divestment activities to tackle its debt

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... Sanofi's $88.3m deal with Ipsen covers the

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... will contribute to a decline in the number of M&A deals over $5bn,

  • Deal Watch January 2017 Deal Watch January 2017

    1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward Pharma. ... 960. Valeant. Sanpower Group. Divestment. Dendreon equity interest. 820. Delinia. Celgene.

  • Deal Watch October 2016 Deal Watch October 2016

    They must have been working eight days a week! Core therapy area acquisitions and non-core divestments are changing the shape of AstraZeneca. ... The Month of Divestments – We Can Work It Out. At least AstraZeneca are making a proactive approach to

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Portfolio Optimisation: Can you really compare Apples to Oranges?

    1] EY Life Sciences Global Corporate Divestment Study -2016 .

  • Global Corporate Divestment Study

    No longer a sign of weakness or failure, divestment in life sciences continued to heat up last year. ... In fact, 87% of life sciences companies say their most recent divestment created long-term value in their remaining company.

  • EY Life Sciences

    No longer a sign of weakness or failure, divestment in life sciences continued to heat up last year. ... In fact, 87% of life sciences companies say their most recent divestment created long-term value in their remaining company.

  • Andrew Waide Associates Ltd

    Company Acquisitions, Divestments and Mergers and Consultancy and Commercial support services.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics